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BLOOD PRESSURE PREDICTION MODEL FOR HYPERTENSIVE 
PATIENTS AT SARABURI HOSPITAL IN 2009
Auamnoy T, Siemmai A, Tantipidoke R
Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: 1. To compare means of calories burnt by exercise (exercise), compli-
ance, eating behavior, hypertension knowledge, age and blood pressure (BP) between 
gender and 2. To ﬁ nd correlations between exercise, compliance, eating behavior 
score, hypertension knowledge, age and blood pressure. 3. To employ Hierarchical 
Stepwise Multiple Regression Analysis (MRA) to predict blood pressure. METHODS: 
A retrospective research by face to face interview and clinical outcomes were used to 
investigate relationships between 6 variables and BP of random 200 hypertensive 
patients at Saraburi Hospital 2009. RESULTS: Total (N) 200 (100%) patients were 
mostly female 118 (59.00%) and 82 (41.00%) were male. The average age was 52.21 
± 12.01 years, average exercise per week 2787.24 ± 141.61 kcal, average compliance 
score 7.41 ± 1.93, average SBP and DBP were 150.24 ± 18.49 and 89.40 ± 9.15 Hgmm. 
Cronbach’s Alpha coefﬁ cient of Sorofman’s Compliance scale for constructs “right 
time” and “right amount” were 0.7978, and 0.7896 respectively, Auamnoy Eating 
Behavior Scale was 0.7915. ANOVA conﬁ rmed that BP, compliance, hypertension 
knowledge, age, exercise and eating behavior score between male and female were not 
signiﬁ cantly different (p > 0.05). Pearson’s correlation conﬁ rmed that age, exercise 
and compliance had signiﬁ cant negative correlation with DBP (r = −0.19, −0.43, −0.60 
with p = 0.00, 0.00, 0.00 respectively). Age had signiﬁ cant positive correlation with 
SBP however exercise and medical regimens compliance had signiﬁ cant negative cor-
relation with SBP (r = 0.16, −0.81, −0.98 with p = 0.02, 0.00, 0.00 respectively). MRA 
equation demonstrated the three most signiﬁ cant variables those predicted SBP and 
DBP were: compliance (Beta = −0.90, −0.70), eating behavior (Beta = 0.82, 0.72) and 
exercise (Beta = −0.11, −0.29) P = 0.00, 0.00, 0.00 R2 = 0.58, 0.55 respectively. 
CONCLUSIONS: The more patients complied to medical regimens, with good eating 
behavior and the more exercise the less patients’ blood pressure was.
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THE MISSING PIECE BETWEEN TREATMENT EXPERIENCE AND 
INTENTION TO PERSIST: TESTING THE INTERNAL CONSISTENCY 
RELIABILITY AND PREDICTIVE VALIDITY OF ACCEPTABILITY
Chretin S1, Viala-Danten M2, Van Ganse E3, Patrick D4, Arnould B2, Longin J1
1Registrat–Mapi, Lyon, France; 2Mapi Values, Lyon, France; 3Hôpital Neurologique Pierre 
Wertheimer, BRON Cedex, France; 4University of Washington, Seattle, WA, USA
OBJECTIVES: The ACCEPT© questionnaire is a self-administered generic accept-
ability instrument assessing how patients balance the advantages and disadvantages 
of long-term chronic therapy. It is made of 2 parts: 1/ several characteristics of patient 
experience with treatment giving an indication on which treatment attributes are 
leading to intentions and adherence; 2/ a scale measuring acceptability of the treat-
ment. Our objective was to test the internal consistency reliability and predictive 
validity of the acceptability scale. METHODS: A survey was conducted in 60 com-
munity pharmacies. Patients treated with statin for more than 3 months were asked 
to complete a preliminary version of the acceptability scale (3 items), as well as ques-
tions regarding their compliance with their statin medication. Compliant patients were 
deﬁ ned as those who reported never to forget to take their statin medication. Internal 
consistency of the acceptability scale was assessed by Cronbach’s alpha. The statistical 
independence between the 3 acceptability items and compliance was investigated by 
chi-2 tests. The ability of the 3 acceptability items to detect non compliant patients 
was evaluated by the area under the Receiver Operating Characteristic (ROC) curve. 
RESULTS: Out of 443 patients included in the analysis, 28% have been treated for 
1 to 3 years, and 54% for more than 3 years. 60% had no cardiovascular antecedent, 
14% had an angina, 13% a prior myocardial infarction, 6% a prior stroke. 66% 
declared they never forgot to take their statin medication. Cronbach’s alpha of the 
acceptability scale was 0.70. The 3 items were statistically related to compliance 
(p-chi2 < 0.0001). The area under the ROC curve was 0.69. CONCLUSIONS: The 
acceptability scale showed satisfying preliminary results of reliability and predictive 
validity. Further work is needed to validate the scale in other long-term treated popula-
tions and to evaluate its ability to predict persistence to treatment over time.
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OBJECTIVES: The primary aim of the study was to determine societal utility scores 
for health states associated with events either beneﬁ ting from aspirin (myocardial 
infarction, stroke, angina) or potentially caused by aspirin (GI bleeding). The second-
ary aim was to determine the societal disutility score of taking aspirin every day. 
METHODS: Draft health states were developed based on a brief literature review and 
exploratory and validation interviews with cardiovascular (n = 3) and stroke (n = 2) 
specialists. The ﬁ nal health states were tested in a pilot study with members of the 
general public (n = 6). In the main study, members of the general public (n = 90 
Canadians; n = 86 Americans) completed a chained standard gamble (SG) interview, 
a Visual Analogue Scale (VAS) rating task (0–100), the EQ-5D and a socio-demo-
graphic form. RESULTS: The samples were a reasonable match to the population of 
Canada and the US in terms of demographics (48% female, 67% white) and quality 
of life (rated by EQ-5D). Eight percent of participants had experienced one or more 
forms of CVD or stroke as described in the health states and 18% of participants were 
taking daily preventive aspirin. In patients who were not taking aspirin, adding daily 
aspirin to prevent CVD caused a decrement in utility of 0.018. Conversely, patients 
who were taking daily aspirin reported an increase in utility of 0.021 compared to if 
they were not taking aspirin. GI bleeding and transient ischemic attack were rated as 
the states with the highest utility (0.79) followed by angina (0.71 stable, 0.66 unsta-
ble). Various stages of MI and stroke were considered least desirable (0.10–0.63). 
CONCLUSIONS: The study highlights the beneﬁ t in utility that could be gained from 
preventing cardiovascular and stroke events. It also demonstrates that the minor 
burden of taking aspirin daily changes to a small incremental beneﬁ t in wellbeing in 
participants already taking aspirin.
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METHODS FOR ESTIMATING HEALTH-STATE UTILITIES IN 
PULMONARY ARTERIAL HYPERTENSION
Mychaskiw MA1, Berger A2, Mardekian J1, Hwang LJ1, Oster G2
1Pﬁ zer Inc, New York, NY, USA; 2Policy Analysis Inc., Brookline, MA, USA
OBJECTIVES: To compare health-state utility values obtained using three different 
instruments administered to patients with pulmonary arterial hypertension (PAH) 
enrolled in a randomized controlled trial of sildenaﬁ l. METHODS: Data for this study 
were obtained from a large phase III clinical trial in which patients were randomized 
to receive either sildenaﬁ l or placebo for 12 weeks. At each visit (baseline, weeks 1, 
4, 8, and 12 of follow-up), patients were administered the Short Form-36 General 
Health Survey (SF-36) and the EuroQol Health Survey (EQ-5D); additionally they also 
were asked to provide a direct assessment of their current health state using a visual 
analog scale (VAS). Responses to the SF-36 and EQ-5D were then converted to health-
state utility values using published algorithms. Patients were pooled across treatment 
groups, and attention was focused on baseline values. Statistical signiﬁ cance of differ-
ences between these three estimates was ascertained using paired t tests. RESULTS: 
There were a total of 274 patients across both treatment groups in the intent-to-treat 
population. Proportions of 0–30, 31–60, and 61–100 health-state utility values were 
0.4%, 22.6%, and 77.0% for SF-36; 16.2%, 9.6%, and 74.3% for EQ-5D; and 8.6%, 
47.2%, and 44.2% for VAS, respectively. Mean (95% conﬁ dence intervals) health-
state utility values were 71.4 (69.6–73.1) for SF-36 (P < 0.01 vs. EQ-5D or VAS), 
63.2 (60.2–66.3) for EQ-5D (P < 0.01 vs. VAS), and 59.0 (56.9–61.2) for VAS, 
respectively. CONCLUSIONS: Ratings of current health by PAH patients are signiﬁ -
cantly worse with a single-item VAS scale than based on responses to the EQ-5D and 
SF-36 health questionnaires. The EQ-5D appears to yield somewhat lower values than 
the SF-36. Further research is needed to better understand the reason(s) for these 
differences.
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SEVENTY-SEVEN HEALTH STATE UTILITIES ESTIMATED IN POLISH 
CARDIAC PATIENTS
Zawodnik S, Golicki D, Hermanowski T
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: The aim of this study was to create a catalogue of SF-6D health state 
utility values in the cardiovascular diseases, based on studies conducted in Polish 
population using the SF-36 questionnaire. METHODS: Five databases: MEDLINE, 
EMBASE, Cochrane Database, SCOPUS, Polish Medical Bibliography (Polska Biblio-
graﬁ a Lekarska; accessed on April 23, 2010) were systematically searched for SF-36 
quality of life studies conducted in Polish cardiac patients. Only studies using original 
key answer and with published complete data for eight SF-36 dimensions were 
included. SF-6D utility scores were estimated based on SF-36 population data using 
the method published by Ara and Brazier in 2009. RESULTS: We initially identiﬁ ed 
31 studies using SF-36 in Polish cardiac patients. In 14 studies proper SF-36 scoring 
algorithm was used and data for all eight domains were available. Data for 77 different 
health states related to ﬁ ve cardiac disorders were extracted: acute coronary syndrome, 
coronary artery disease, hypertension, atrial ﬁ brillation and aortic valve disease. Each 
health state was described as value of 8 dimensions of quality of life and was converted 
to single-ﬁ gure utility. Utility of acquired 77 health states ranged from 0.41 to 0.78. 
CONCLUSIONS: A catalogue of 77 health state utilities derived in Polish cardiac 
patients was estimated. It can be useful in pharmacoeconomic analyses conducted for 
cardiologic health technologies and should support reimbursement decision making 
in Poland.
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HOW PATIENTS’ EXPERIENCE COULD INFLUENCE THEIR 
PREFERENCES TOWARD TREATMENT FOR ABDOMINAL AORTIC 
ANEURYSM: RESULTS FROM THE PREFER STUDY
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OBJECTIVES: Factors inﬂ uencing preferences towards treatment of abdominal aortic 
aneurysm (AAA) were scarcely investigated. To identify how patients’ experience can 
affect their preferences for treatment of AAA. METHODS: within a multicentre 
Discrete-Choice-Study aimed to assess preferences toward AAA treatment the partici-
pant patients responded to 4 pair-wise choice sets comparing treatment options 
obtained from a factorial combination of 6 characteristics: type of anaesthesia 
(general vs. local); recovery time to everyday basic activities (2 vs. 4 days); risk of 
